基于DRD4/NOX4通路探讨左归丸改善肾阴虚型甲亢大鼠氧化应激的作用机制OA
Zuoguiwan Mitigates Oxidative Stress in Rat Model of Hyperthyroidism Due to Kidney-Yin Deficiency via DRD4/NOX4 Pathway
目的:基于多巴胺受体D4(DRD4)/还原型辅酶Ⅱ氧化酶4(NOX4)信号通路,探讨左归丸治疗甲亢肾阴虚型大鼠的作用机制.方法:采用单侧肌肉注射地塞米松(0.35 mg·kg-1)诱导肾阴虚模型,造模成功后随机分为模型组,甲巯咪唑组(5 mg·kg-1)及左归丸低、中、高剂量组(1.85、3.70、7.40 g·kg-1),另设正常组.连续灌胃给药21 d后,评估大鼠行为学指标及体质量变化;通过苏木素-伊红(HE)染色观察肾组织病理形态;酶联免疫吸附测定法(ELISA)检测血清甲状腺激素三碘甲状腺原氨酸(T3)、四碘甲状腺素(T4)、促甲状腺激素(TSH)、肾功能指标血清肌酐(Scr)、血尿素氮(BUN)、能量代谢标志物环磷酸腺苷(cAMP)、环磷酸鸟苷(cGMP)及氧化应激相关因子超氧化物歧化酶(SOD)、丙二醛(MDA)、还原型辅酶Ⅱ(NADPH)水平;蛋白免疫印迹法(Western blot)检测肾组织中DRD4、NOX4、线粒体呼吸链复合体蛋白泛醌氧化还原酶亚基S4(NDUFS4)、细胞色素C氧化酶 4(COX4)及炎症相关蛋白肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、p38 丝裂原活化蛋白激酶(p38 MAPK)信号通路相关蛋白的表达.结果:与正常组比较,模型组大鼠表现为精神萎靡、体质量显著降低(P<0.01),肾组织出现炎细胞浸润,甲状腺出现少数腮后腺体残留,血清T3、T4、Scr、BUN、cAMP、cAMP/cGMP、MDA及NADPH水平显著升高(P<0.01),TSH、SOD及DRD4蛋白表达明显降低(P<0.05,P<0.01),NOX4、磷酸化(p)-p38 MAPK/p38 MAPK及炎症因子表达上调(P<0.01).与模型组比较,左归丸干预后大鼠体质量明显增加(P<0.05,P<0.01),肾间质炎细胞浸润减少,甲状腺结构完整,滤泡大小均匀,血清T3、T4、Scr、BUN、cAMP、cAMP/cGMP、MDA及NADPH水平明显降低(P<0.05,P<0.01),TSH、SOD及DRD4蛋白表达明显升高(P<0.05,P<0.01),NOX4、p-p38 MAPK/p38 MAPK及炎症因子表达明显降低(P<0.05,P<0.01),且高剂量组疗效优于甲巯咪唑组(P<0.05).结论:左归丸通过激活DRD4受体,抑制p38 MAPK通路介导的NOX4表达,减轻氧化应激及炎症反应,从而改善甲亢肾阴虚型的病理状态.该研究为左归丸的临床应用提供了新的分子机制支持.
Objective:To decipher the mechanism by which Zuoguiwan(ZGW)treat hyperthyroidism in rats with kidney-Yin deficiency based on the dopamine receptor D4(DRD4)/nicotinamide adenine dinucleotide phosphate(NADPH)oxidase 4(NOX4)signaling pathway.Methods:The rat model of kidney-Yin deficiency was induced by unilateral intramuscular injection of dexamethasone(0.35 mg·kg-1).After successful modeling,the rats were randomized into model,methimazole(positive control,5 mg·kg-1),low-,medium-,and high-dose(1.85,3.70,7.40 g·kg-1,respectively)ZGW,and normal control groups.After 21 days of continuous gavage,the behavioral indexes and body weight changes of rats were evaluated.The pathological changes of the renal tissue were observed by hematoxylin-eosin staining.The serum levels of thyroid hormones[triiodothyronine(T3),thyroxine(T4),thyroid-stimulating hormone(TSH)],renal function indexes[serum creatine(Scr)and blood urea nitrogen(BUN)],energy metabolism markers[cyclic adenosine monophosphate(cAMP)and cyclic guanosine monophosphate(cGMP)],and oxidative stress-related factors[superoxide dismutase(SOD),malondialdehyde(MDA),and NADPH)]were measured by enzyme-linked immunosorbent assay(ELISA).Western blot was employed to analyze the expression of DRD4,NOX4,mitochondrial respiratory chain complex proteins[NADH:ubiquinone oxidoreductase subunit S4(NDUFS4)and cytochrome C oxidase subunit 4(COX4)],and inflammation-related protein[tumor necrosis factor-alpha(TNF-α),interleukin-6(IL-6),p38 mitogen-activated protein kinase(MAPK)]pathway in the renal tissue.Results:Compared with the normal group,the model group showed mental malaise,body weight decreases(P<0.01),inflammatory cell infiltration in the renal tissue,a few residual parotid glands in the thyroid,elevations in serum levels of T3,T4,Scr,BUN,cAMP,cAMP/cGMP,MDA,and NADPH(P<0.01),down-regulation in protein levels of TSH,SOD,and DRD4(P<0.05,P<0.01),and up-regulation in expression of NOX4,p-p38 MAPK/p38 MAPK,and inflammatory factors(P<0.01).Compared with the model group,ZGW increased the body weight(P<0.05,P<0.01),reduced the infiltration of renal interstitial inflammatory cells,restored the thyroid structure and follicle size,lowered the serum levels of T3,T4,Scr,BUN,cAMP,cAMP/cGMP,MDA and NADPH(P<0.05,P<0.01),up-regulated the expression of TSH,SOD and DRD4(P<0.05,P<0.01),and down-regulated the expression of NOX4,p-p38 MAPK/p38 MAPK,and inflammatory factors(P<0.05,P<0.01).Moreover,high-dose ZGW outperformed methimazole(P<0.05).Conclusion:By activating DRD4,ZGW can inhibit the expression of NOX4 mediated by the p38 MAPK pathway,reduce oxidative stress and inflammatory response,thereby ameliorating the pathological state of hyperthyroidism due to kidney-Yin deficiency.This study provides new molecular mechanism support for the clinical application of ZGW.
林玲;杨蕾;梁茜铭;邓长生;茹丽;徐志勇;李超;沈铭舜;员月明;李木子
广州中医药大学 青蒿研究中心,广州 501405广州中医药大学 中药学院,广州 510006广州中医药大学 青蒿研究中心,广州 501405广州中医药大学 青蒿研究中心,广州 501405||中国中医科学院 中药研究所 道地药材品质保障与资源持续利用全国重点实验室,北京 100700广州中医药大学 科技产业园,广州 510445广州中医药大学 科技产业园,广州 510445广州中医药大学 科技产业园,广州 510445广州中医药大学 科技产业园,广州 510445广州中医药大学 科技产业园,广州 510445北京同仁堂科技发展股份有限公司制药厂,北京 100079
医药卫生
甲亢肾阴虚型左归丸氧化应激多巴胺受体D4(DRD4)还原型辅酶Ⅱ氧化酶4(NOX4)
hyperthyroidism due to kidney-Yin deficiencyZuoguiwanoxidative stressdopamine receptor D4(DRD4)NADPH oxidase 4(NOX4)
《中国实验方剂学杂志》 2026 (2)
43-51,9
中央本级重大增减支项目"名贵中药资源可持续利用能力建设项目"(2060302)广州市科技计划项目(202206010066)广东省自然科学基金项目(2018A0303130072)
评论